Search Result

Results for "

HDAC inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HDAC (386) Adenosine Receptor (7) Akt (1) Aminopeptidase (1) AMPK (1) Amyloid-β (3) Anaplastic lymphoma kinase (ALK) (1) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (123) Autophagy (40) Bcl-2 Family (2) Bcr-Abl (1) Beta-lactamase (5) c-Met/HGFR (2) Calcium Channel (1) Caspase (4) CCR (1) CDK (5) Cholinesterase (ChE) (5) COX (1) Cytochrome P450 (2) DNA/RNA Synthesis (3) Drug-Linker Conjugates for ADC (2) EBV (1) EGFR (1) Endogenous Metabolite (14) Epigenetic Reader Domain (3) Epoxide Hydrolase (1) Ferroptosis (1) FGFR (1) Filovirus (2) FLT3 (2) Fluorescent Dye (1) Fungal (3) G Protein-coupled Receptor Kinase (GRK) (1) G-quadruplex (1) Guanylate Cyclase (1) HIF/HIF Prolyl-Hydroxylase (2) Histone Acetyltransferase (1) Histone Demethylase (5) Histone Methyltransferase (3) HIV (17) HPV (2) HSP (4) iGluR (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Influenza Virus (1) Interleukin Related (5) Isotope-Labeled Compounds (8) JAK (5) Keap1-Nrf2 (1) MDM-2/p53 (3) Microtubule/Tubulin (8) Mitochondrial Metabolism (1) Mitophagy (14) MMP (1) Monoamine Oxidase (3) mTOR (5) MyD88 (1) NAMPT (2) Necroptosis (1) NF-κB (4) Notch (10) Organoid (3) Oxidative Phosphorylation (1) PAK (1) Parasite (8) PARP (3) Phosphatase (1) Phosphodiesterase (PDE) (6) PI3K (8) Pim (1) PKD (1) Potassium Channel (1) PROTACs (2) Proteasome (1) Reactive Oxygen Species (5) SHP2 (1) Sirtuin (1) Sodium Channel (1) Tau Protein (1) TNF Receptor (4) Toll-like Receptor (TLR) (1) Topoisomerase (3) Tyrosinase (1) VEGFR (2) Virus Protease (5)
By Research Areas:	Cancer (333) Cardiovascular Disease (7) Endocrinology (2) Infection (24) Inflammation/Immunology (24) Metabolic Disease (8) Neurological Disease (45)
Click Chemistry:	Alkynes (7)

408

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: HDAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-162086

HDAC-IN-68	HDAC	Cancer
HDAC-IN-68 (Compound 29) is a potent HDAC inhibitor that disrupts microtubule structure and inhibits tumor growth. HDAC-IN-68 significantly inhibits class I HDACs (HDAC1, HDAC2, HDAC3) with IC₅₀ values of 5.1, 11.5 and 8.8 nM, respectively .

HY-157152

HDAC-IN-65	HDAC	Cancer
HDAC-IN-65 ( compound 6) is a selective histone deacetylase (HDAC) inhibitor with IC₅₀ value of 2.5μM. HDAC-IN-65 is a prodrug with very good bioreductive properties .

HY-130493

HPB

HDAC6 inhibitor HPB
HDAC Cancer

HPB (HDAC6 inhibitor HPB) is a selective HDAC6 inhibitor with an IC₅₀ of 31 nM. HPB exhibits >30-flod selectivity for HDAC6 over HDAC1 .
HY-149529

HDAC8-IN-5

HDAC Cancer

HDAC8-IN-5 (Compound 6a) is a HDAC8 inhibitor (IC₅₀: 28 nM). HDAC8-IN-5 can be used for cancer research .
HY-144102

HDAC-IN-29

HDAC Cancer

HDAC-IN-29 (compound 13b) is a potent pan-HDAC inhibitor. HDAC-IN-29 shows antitumor activity .

HPB HDAC6 inhibitor HPB	HDAC	Cancer
HPB (HDAC6 inhibitor HPB) is a selective *HDAC6* inhibitor with an IC₅₀ of 31 nM. HPB exhibits >30-flod selectivity for HDAC6 over HDAC1 .

HDAC8-IN-5	HDAC	Cancer
HDAC8-IN-5 (Compound 6a) is a *HDAC8* inhibitor (IC₅₀: 28 nM). HDAC8-IN-5 can be used for cancer research .

HDAC-IN-29	HDAC	Cancer
HDAC-IN-29 (compound 13b) is a potent pan-HDAC inhibitor. HDAC-IN-29 shows antitumor activity .

HY-112147

IDO1 and HDAC1 Inhibitor	Indoleamine 2,3-Dioxygenase (IDO) HDAC	Cancer
IDO1 and HDAC1 Inhibitor (Compound 10) is a dual IDO1 and *HDAC1* inhibitor with IC₅₀s of 69.0 nM and 66.5 nM, respectively .

HY-151897

HDAC-IN-49	HDAC	Cancer
HDAC-IN-49 is a potent unselective *HDAC* (HDAC) inhibitor with IC₅₀s of 13 nM, 14 nM, 21 nM, 1880 nM, and 10 nM for HDAC1, HDAC2, HDAC3, HDAC4, and HDAC6. HDAC-IN-49 demonstrates prominent antileukemic activity with low cytotoxic activity toward healthy cells .

HY-150577

HDAC-IN-45	HDAC	Cancer
HDAC-IN-45 (Compound 14) is a small molecule *HDAC* inhibitor and has anticancer activity, also can forms a hydrogen bond with residue Y303. HDAC-IN-45 (Compound 14) has substantial inhibitory effects towards HDAC1, 2 and 3 isoforms with IC₅₀ values of 0.108, 0.585 and 0.563 μM respectively .

HY-157215

HDAC-IN-66

HDAC Cancer

HDAC-IN-66 (compound 2F) is a selective HDAC inhibitor and Pomalidomide (HY-10984) derivative that potently inhibits hematological tumor cells .
HY-117394

MD 85

HDAC Cancer

MD 85 is a potent histone deacetylase (HDAC) inhibitor with an EC₅₀ of 5 μM. MD 85 can be used for cancer research .

HDAC-IN-66	HDAC	Cancer
HDAC-IN-66 (compound 2F) is a selective *HDAC* inhibitor and Pomalidomide (HY-10984) derivative that potently inhibits hematological tumor cells .

MD 85	HDAC	Cancer
MD 85 is a potent histone deacetylase (HDAC) inhibitor with an EC₅₀ of 5 μM. MD 85 can be used for cancer research .

HY-142706

MAO A/HDAC-IN-1	Monoamine Oxidase HDAC	Cancer
MAO A/HDAC-IN-1 is a dual?inhibitor?of monoamine oxidase A (MAO A) and *HDAC. MAO A/HDAC-IN-1 can be used for glioma research . MAO A/HDAC*-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-144332

PHD2/HDACs-IN-1	HDAC HIF/HIF Prolyl-Hydroxylase	Cancer
PHD2/HDACs-IN-1 is a potent *PHD2/HDACs* hybrid inhibitor (IC₅₀s of 1.15 μM, 19.75 μM, 26.60 μM and 15.98 μM for PHD2, HDAC1, HDAC2 and HDAC6, respectively). PHD2/HDACs-IN-1 is a low-toxicity renoprotective agent for research of cisplatin-induced acute kidney injury (AKI) .

HY-156094

JMJD3/HDAC-IN-1	HDAC Histone Demethylase Apoptosis	Cancer
JMJD3/HDAC-IN-1 (compound A5b) is a dual inhibitor targeting Jumonji domain-containing protein demethylase 3 (JMJD3) and histone deacetylase (HADC1, IC₅₀=16 nM). JMJD3/HDAC-IN-1 promotes hypermethylation of histone H3K27 and hyperacetylation of H3K9, and also cleaves caspase-7 and PARP to induce apoptosis. JMJD3/HDAC-IN-1 effectively inhibits cancer cell cloning, migration, and invasion .

HY-161304

HDAC6-IN-33	HDAC	Cancer
HDAC6-IN-33 (compound 6) is a selective and irreversible *HDAC6* inhibitor with an IC₅₀ of 193 nM. HDAC6-IN-33 shows no activity against HDAC1-4. HDAC6-IN-33 is a tight-binding HDAC6 inhibitor capable of inhibiting HDAC6 via a two-step slow-binding mechanism .

HY-153583

HDAC8-IN-4

HDAC Cancer

HDAC8-IN-4 is a selective inhibitor of HDAC8. HDAC8-IN-4 inhibits HDAC8 and HDAC3 with IC₅₀s of 0.15 and 12 μM .
HY-151896

HDAC6-IN-14

HDAC Cancer

HDAC6-IN-14 is a highly selective HDAC6 (HDAC) inhibitor with an IC₅₀ of 42 nM. HDAC6-IN-14 displays >100-fold selectivity over HDAC1/HDAC2/HDAC3/HDAC4 .

HDAC8-IN-4	HDAC	Cancer
HDAC8-IN-4 is a selective inhibitor of *HDAC8. HDAC8-IN-4 inhibits* HDAC8 and HDAC3 with IC₅₀s of 0.15 and 12 μM .

HDAC6-IN-14	HDAC	Cancer
HDAC6-IN-14 is a highly selective *HDAC6* (HDAC) inhibitor with an IC₅₀ of 42 nM. HDAC6-IN-14 displays >100-fold selectivity over HDAC1/HDAC2/HDAC3/HDAC4 .

HY-18998

LMK-235 15+ Cited Publications	HDAC	Cancer
LMK-235 is a potent and selective *HDAC4/5* inhibitor, inhibits HDAC5, HDAC4, HDAC6, HDAC1, HDAC2, HDAC11 and HDAC8, with IC₅₀s of 4.22 nM, 11.9 nM, 55.7 nM, 320 nM, 881 nM, 852 nM and 1278 nM, respectively, and is used in cancer research.

HY-149497

HDAC6-IN-19	HDAC	Cancer
HDAC6-IN-19 (Compound 14g) is a *HDAC6* inhibitor (IC₅₀: 2.68 nM). HDAC6-IN-19 also inhibits HDAC1, HDAC2 and HDAC3 with IC₅₀s of 61.6 nM, 98.7 nM and 103 nM. HDAC6-IN-19 potently inhibits multiple cancer cell proliferation, including leukemia, colon cancer, melanoma, and breast cancer cell lines .

HY-18700

BRD73954 3 Publications Verification	HDAC	Cancer
BRD73954 is a potent *HDAC* inhibitor and selectively inhibiting both HDAC6 and HDAC8 with IC₅₀ values of 0.0036, 0.12, 9, 12, 23 µM for HDAC6, HDAC8, HDAC2, HDAC1 and HDAC3, respectively. BRD73954 decreases the levels of HDAC6, associated with upregulation of Ac-Tubulin .

HY-101780

Tinostamustine 3 Publications Verification EDO-S101; NL-101	HDAC	Cancer
Tinostamustine (EDO-S101) is a pan *HDAC* inhibitor; inhibits *HDAC6, HDAC1, HDAC2* and *HDAC3* with IC₅₀ values of 6 nM, 9 nM, 9 nM and 25 nM, respectively .

HY-161155

HDAC6-IN-31	HDAC	Inflammation/Immunology
HDAC6-IN-31 (compound 8m) is a selective HDAC6 inhibitor, with the IC₅₀ value of 0.026 μM, that significantly inhibits the production and release of pro-inflammatory cytokines. While HDAC6 is critically involved in the activation of inflammasomes, HDAC6-IN-31 has the potential to inhibit NLRP3 inflammasome-driven inflammatory diseases. HDAC6-IN-31 also inhibits glioblastoma cell migration .

HY-157385

HDAC-IN-67	HDAC Apoptosis	Cancer
HDAC-IN-67 (compound 27f) is an *HDAC* inhibitor against HDAC1 and HDAC6, with IC₅₀ values of 22 nM and 8 nM, respectively. HDAC-IN-67 inhibits cell proliferation and induces cell apoptosis. HDAC-IN-67 exhibits antitumor activity .

HY-147731

HDAC6-IN-9	HDAC	Cancer
HDAC6-IN-9 (compound 12c) is a potent and selective *HDAC6* inhibitor with IC₅₀ values of 11.8, 15.2, 4.2, 139.6, 21.3 nM for HDAC1,HDAC3, HDAC6, HDAC8, HDAC10, respectively. HDAC6-IN-9 shows anti-proliferative activities .

HY-161154

HDAC3-IN-3

HDAC Cancer

HDAC3-IN-3 (compound 31) is a potent HDAC3 inhibitor. HDAC3-IN-3 has the potential for the research of cancer .

HDAC3-IN-3	HDAC	Cancer
HDAC3-IN-3 (compound 31) is a potent *HDAC3* inhibitor. HDAC3-IN-3 has the potential for the research of cancer .

HY-151261

HDAC6-IN-13	HDAC	Inflammation/Immunology
HDAC6-IN-13 (Compound 35m) is a potent, highly selective, orally active *HDAC6* inhibitor with an IC₅₀ of 0.019 μM. HDAC6-IN-13 also inhibits *HDAC1, HDAC2* and *HDAC3* with IC₅₀s of 1.53, 2.06 and 1.03 μM, respectively. HDAC6-IN-13 shows significant BBB permeability and anti-inflammatory activity .

HY-111342

HDAC8-IN-1

2 Publications Verification

HDAC Cancer

HDAC8-IN-1 is a HDAC8 inhibitor with an IC₅₀ of 27.2 nM.

HDAC8-IN-1 2 Publications Verification	HDAC	Cancer
HDAC8-IN-1 is a *HDAC8* inhibitor with an IC₅₀ of 27.2 nM.

HY-157314

HDAC6-IN-27	HDAC Parasite	Infection
HDAC6-IN-27 (compound 8C) is a *HDAC* inhibitor with IC₅₀ vales of 15.9 nM 136.5 nM and 6180.2 nM for HDAC6, HDAC8 and HDAC1, respectively. HDAC6-IN-27 shows potent antiparasitic effects .

HY-151248

HDAC2-IN-1	HDAC	Neurological Disease
HDAC2-IN-1 (Compound 17) is a brain penetrant, orally active, competitive *HDAC2* inhibitor with an IC₅₀ of 0.5 μM . HDAC2-IN-1 also inhibits *HDAC1* and *HDAC8* with IC₅₀s of 1.61 μM and 0.98 μM, respectively .

HY-149946

HDAC-IN-57	HDAC Apoptosis Histone Demethylase
HDAC-IN-57 is an orally active inhibitor of histone deacetylases (HDAC), with IC₅₀s of 2.07 nM, 4.71 nM, 2.4 nM and 107 nM for HDAC1, HDAC2, HDAC6, HDAC8, respectively. HDAC-IN-57 can inhibits LSD1, with IC₅₀ of 1.34 μΜ. HDAC-IN-57 induces apoptosis, and has anti-tumor activity .

HY-18361

TMP195 10+ Cited Publications	HDAC	Cancer
TMP195 is a selective class IIa histone deacetylase (HDAC) inhibitor with K_is of 59, 60, 26, 15 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.

HY-146153

HDAC-IN-40	HDAC	Cancer
HDAC-IN-40 is a potent alkoxyamide-based *HDAC* inhibitor with K_i values of 60 nM and 30 nM for *HDAC2* and *HDAC6, respectively. HDAC*-IN-40 had antitumor effects .

HY-163143

HDAC8-IN-6

HDAC Cancer

HDAC8-IN-6 (compound 3) is a potent HDAC8 inhibitor with an IC₅₀ of 5.1 μM. HDAC8-IN-6 shows cytotoxicity .
HY-149646

HDAC6-IN-24

HDAC Cancer

HDAC6-IN-24 (compound N1) is a inhibitor of HDAC6 .
HY-157219

HDAC6-IN-26

HDAC Cancer

HDAC6-IN-26 (compound 23) is a potent inhibitor of HDAC6 .

HDAC8-IN-6	HDAC	Cancer
HDAC8-IN-6 (compound 3) is a potent *HDAC8* inhibitor with an IC₅₀ of 5.1 μM. HDAC8-IN-6 shows cytotoxicity .

HDAC6-IN-24	HDAC	Cancer
HDAC6-IN-24 (compound N1) is a inhibitor of *HDAC6* .

HDAC6-IN-26	HDAC	Cancer
HDAC6-IN-26 (compound 23) is a potent inhibitor of *HDAC6* .

HY-155182

HDAC-IN-62	HDAC Autophagy	Neurological Disease Inflammation/Immunology
HDAC-IN-62 (Compound 5) a *HDAC* inhibitor, with IC₅₀s of 0.78, 1.0, 1.2? μM for HDAC6/8/11 respectively. HDAC-IN-62 inhibits-induced microglial activation by the initiation of autophagy, and inhibits nitric oxide production. HDAC-IN-62 has anti-inflammatory and anti-depressant effects. HDAC-IN-62 inhibits microglial activation in mouse brain .

HY-139650

HDAC1/2-IN-3

HDAC Cancer

HDAC1/2-IN-3 is a HDAC1 and HDAC2 inhibitor with IC₅₀ values 0-5 and 5-10 nM, respectively.

HDAC1/2-IN-3	HDAC	Cancer
HDAC1/2-IN-3 is a **HDAC1 and HDAC2** inhibitor with IC₅₀ values 0-5 and 5-10 nM, respectively.

HY-12164

Mocetinostat 10+ Cited Publications MGCD0103	HDAC Autophagy Apoptosis	Cancer
Mocetinostat (MGCD0103) is a potent, orally active and isotype-selective HDAC (Class I/IV) inhibitor with IC₅₀s of 0.15, 0.29, 1.66 and 0.59 μM for *HDAC1, HDAC2, HDAC3* and *HDAC11, respectively. Mocetinostat shows no inhibition on HDAC4, HDAC5, HDAC6, HDAC7, or HDAC*8.

HY-149372

HDAC6-IN-17	HDAC	Cancer
HDAC6-IN-17 (compound 5b) is a potent *HDAC6* inhibitor with IC₅₀ values of 150 nM, 1400 nM, and 2300 nM for HDAC6, HDAC8, and HDAC4, respectively. HDAC6-IN-17 has cytotoxic activity on human cancer cell lines. HDAC6-IN-17 can be used in research of cancer .

HY-15144B

(S)-Trichostatin A (S)-TSA	HDAC	Cancer
(S)-Trichostatin A ((S)-TSA) is a *HDAC6*-selective inhibitor with IC₅₀s of 9.88 nM and 11.1 nM for Zebrafish HDAC6 and Human HDAC6, respectively. (S)-Trichostatin A weakly inhibits other human HDACs .

HY-152235

HDAC6-IN-15	HDAC	Neurological Disease Cancer
HDAC6-IN-15 is a selective histone deacetylase 6 (HDAC6) inhibitor. HDAC6-IN-15 has potent inhibitory activity for HDAC6 with IC₅₀ value of 38.2 nM. HDAC6-IN-15 can be used for the research of cancer and neurodegenerative diseases .

HY-163430

HDAC-IN-71	HDAC Apoptosis	Cancer
HDAC-IN-71 (Compound 17q) is a potent *HDAC* inhibitor with IC₅₀ values of 12.6, 14.1, 20, 3, and 72 nM for HDAC1, HDAC2, HDAC3, HDAC6, and HDAC10, respectively. HDAC-IN-71 induces apoptosis and can be used in cancer research .

HY-156274

HDAC6-IN-23

HDAC Cancer

HDAC6-IN-23 (compound 9) is an orally active HDAC6 inhibitor .

HDAC6-IN-23	HDAC	Cancer
HDAC6-IN-23 (compound 9) is an orally active *HDAC6* inhibitor .

HY-16425

RG2833 5 Publications Verification RGFP109	HDAC	Cancer
RG2833 is a brain-penetrant *HDAC* inhibitor with IC₅₀s of 60 nM and 50 nM for HDAC1 and HDAC3, respectively. The K_i values for HDAC1 and HDAC3 are 32 and 5 nM, respectively .

HY-13592

HDAC-IN-7 Chidamide impurity	HDAC	Cancer
HDAC-IN-7 (Chidamide impurity) is an impurity of Chidamide. Chidamide is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor.

HY-10221

Vorinostat 85+ Cited Publications SAHA; Suberoylanilide hydroxamic acid	HDAC Autophagy Mitophagy Filovirus Apoptosis HPV	Infection Cancer
Vorinostat (SAHA) is a potent and orally active pan-inhibitor of *HDAC1, HDAC2* and HDAC3 (Class I), *HDAC6* and HDAC7 (Class II) and HDAC11 (Class IV), with ID₅₀ values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis . Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification .

HY-149371

HDAC6-IN-16	HDAC Apoptosis	Cancer
HDAC6-IN-16 (compound 5c) is a histone deacetylase 6 (HDAC6) inhibitor, based on Quinazolin-4(3H)-One. HDAC6-IN-16 exhibits anticancer effect, inhibits colony-forming. And HDAC6-IN-16 arrests cell cycle at G2 phase and induces apoptosis .

HY-18613

CAY10603 4 Publications Verification BML-281	HDAC	Cancer
CAY10603 (BML-281) is a potent and selective *HDAC6* inhibitor, with an IC₅₀ of 2 pM; CAY10603 (BML-281) also inhibits HDAC1, HDAC2, HDAC3, HDAC8, HDAC10, with IC₅₀s of 271, 252, 0.42, 6851, 90.7 nM.

HY-114548

Ebselen oxide	Guanylate Cyclase	Infection
Ebselen oxide, the selenone analogue of Ebselen, covalently modifies diguanylate cyclase (DGC) to inhibit c-di-GMP-receptor interactions and reduces DGC activity. Ebselen oxide also inhibits alginate production (IC₅₀=14 μM) by Pseudomonas aeruginosa. Ebselen oxide inhibits HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9 (IC₅₀ ranging from 0.2 to 4.7 μM) .

HY-150722

HDAC6-IN-12	HDAC	Cancer
HDAC6-IN-12 (compound GZ) is a potent *HDAC6* inhibitor. HDAC6-IN-12 has anticancer activity through merges into DNA strands causing DNA damage. HDAC6-IN-12 can be used for cancer research .

HY-152174

HDAC-IN-52	HDAC	Cancer
HDAC-IN-52 is a pyridine-containing *HDAC* inhibitor, with IC₅₀s of 0.189, 0.227, 0.440 and 0.446 μM for *HDAC1, HDAC2, HDAC3, and HDAC10, respectively. HDAC*-IN-52 can be used for the research of cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-15144

Trichostatin A Maximum Cited Publications 108 Publications Verification TSA	Structural Classification Classification of Application Fields Anti-aging Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Cancer	Organoid HDAC
Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC₅₀ value of 1.8 nM for HDAC .

HY-N11692

9-Hydroxyoctadecanoic acid 9-Hydroxystearic acid; 9-HSA	Apocynaceae Structural Classification Strophanthus sarmentosus DC. Ketones, Aldehydes, Acids Source classification Plants	HDAC
9-Hydroxyoctadecanoic acid (9-HSA) is an *HDAC1* inhibitor that inhibits ∼66.4% HDAC1 enzymatic activity at 5 μM. 9-Hydroxyoctadecanoic acid shows anticancer activity .

HY-N0141

Parthenolide 20+ Cited Publications (-)-Parthenolide	Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Compositae Euchresta formosana (Hayata) Ohwi Disease Research Fields Cancer	NF-κB Autophagy Mitophagy Apoptosis
Parthenolide is a sesquiterpene lactone found in the medicinal herb Feverfew. Parthenolide exhibits anti-inflammatory activity by inhibiting NF-κB activation; also inhibits *HDAC1* protein without affecting other class I/II HDACs.

HY-10585A

Valproic acid sodium 30+ Cited Publications Sodium Valproate sodium	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (Sodium Valproate) sodium is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid sodium activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585

Valproic acid 30+ Cited Publications Dipropylacetic Acid	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585B

Valproic acid (sodium)(2:1) VPA (sodium)(2:1); 2-Propylpentanoic Acid (sodium)(2:1)	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) sodium (2:1) is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid sodium (2:1) activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-N0071

Crotonoside Isoguanosine	Alkaloids Structural Classification Classification of Application Fields Croton tiglium Linn. Source classification Euphorbiaceae Plants Disease Research Fields Cancer	FLT3 HDAC
Crotonoside is isolated from Chinese medicinal herb, Croton. Crotonoside inhibits FLT3 and *HDAC3/6*, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the research of AML .

HY-135476

Depudecin (-)-Depudecin	Structural Classification Natural Products Source classification Plants Brassicaceae Brassica campestris L.	HDAC
Depudecin ((-)-Depudecin) is a histone deacetylase (HDAC) inhibitor. Depudecin can be isolated from the fungus Alternaria brassicicola .

HY-N4315

Pomiferin NSC 5113	Classification of Application Fields Source classification Phenols Polyphenols Maclura pomifera (Raf.) Schneid. Plants Moraceae Disease Research Fields Cancer	HDAC mTOR
Pomiferin (NSC 5113) acts as an potential inhibitor of *HDAC, with an IC₅₀* of 1.05 μM, and also potently inhibits mTOR (IC₅₀, 6.2 µM).

HY-N6017

Bakkenolide A	Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Compositae Disease Research Fields Cancer Corethrodendron multijugum (Maximowicz) B. H. Choi & H. Ohashi	HDAC
Bakkenolide A is a natural product extracted from Petasites tricholobus. Bakkenolide A inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways .

HY-P2698

1-Alaninechlamydocin	Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields Cancer	HDAC Apoptosis
1-Alaninechlamydocin, a cyclic tetrapeptide, is a potent *HDAC* inhibitor (IC₅₀=6.4 nM). 1-Alaninechlamydocin induces G2/M cell cycle arrest and apoptosis in MIA PaCa-2 cells .

HY-N0931

Santacruzamate A 5+ Cited Publications CAY-10683	Alkaloids Structural Classification Microorganisms other families Classification of Application Fields Other Alkaloids Source classification Plants Disease Research Fields Cancer	HDAC Amyloid-β
Santacruzamate A (CAY-10683, STA) is a potent and selective HDAC2 inhibitor with an IC₅₀ of 119 pM. STA also exerts neuroprotective property against amyloid-β protein fragment 25–35. STA can be used for cancer and neurological disease research .

HY-N2345

Procyanidin B3	Flavonoids other families Classification of Application Fields Functional Molecules Source classification Research of Health Products Phenols Polyphenols Plants Biflavones Disease Research Fields Cancer	Histone Acetyltransferase
Procyanidin B3 is a natural product, acts as a specific HAT inhibitor, binds to the other site of p300 instead of the active site, selectively inhibits p300-mediated androgen receptor acetylation. Procyanidin B3 has no effect on HDAC or HMT (histone methyltransferase) .

HY-126566

Trichostatin C	Structural Classification Natural Products Microorganisms Source classification	Fungal HDAC Apoptosis
Trichostatin C is an inhibitor for histone deacetylase (HDAC), induces apoptosis and arrests cell cycle at G2/M phase, and exhibits anticancer activity against lung cancer and urothelial bladder cancer . Trichostatin C induces differentation of Friend leukemic cells . Trichostatin C exhibits antifungal activity .

HY-N8707

Homobutein	Classification of Application Fields Source classification Plants Compositae Infection Chalcones Flavonoids Millettia pachyloba Drake Phenols Polyphenols Inflammation/Immunology Disease Research Fields Cancer	Parasite HDAC NF-κB
Homobutein a natural chalcones (can be found in many medicinal plants, fruits, vegetables, spices and nuts), is a potent *HDACs/NF-κB* dual inhibitor with IC₅₀s of 190 and 38 μM, respectively. Homobutein also a chelator of iron (II and III) cations, shows various activities, including anticancer, anti-inflammatory, antiparasite and antioxidation .

HY-N2609

7,4'-Dihydroxyflavone 1 Publications Verification	Structural Classification Flavonoids Classification of Application Fields Flavones Leguminosae Source classification Phenols Polyphenols Plants Disease Research Fields Glycyrrhiza uralensis Fisch. Endocrinology	CCR NF-κB
7,4'-Dihydroxyflavone (7,4'-DHF) is a flavonoid, which can be isolated from Glycyrrhiza uralensis. 7,4'-Dihydroxyflavone is eotaxin/CCL11 inhibitor and CBR1 inhibitor (IC₅₀=0.28 μM). 7,4'-Dihydroxyflavone has the ability to consistently suppress eotaxin production and prevent dexamethasone (Dex)‐paradoxical adverse effects on eotaxin production . 7,4'-Dihydroxyflavone (7,4'-DHF) inhibits MUC5AC gene expression, mucus production and secretion via regulation of NF-κB, STAT6 and HDAC2.7,4'-Dihydroxyflavone (7,4'-DHF) decreases phorbol 12-myristate 13-acetate (PMA) stimulated NCI-H292 human airway epithelial cell MUC5AC gene expression and mucus production with IC₅₀ value of 1.4 µM .

HY-126052

Gnetol	Structural Classification Stilbenes Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Gnetaceae Plants Disease Research Fields Gnetum montanum Markgr.	COX Tyrosinase HDAC
Gnetol is a phenolic compound isolated from the root of Gnetum montanum . Gnetol potently inhibits COX-1 (IC₅₀ of 0.78 μM) and *HDAC. Gnetol is a potent tyrosinase* inhibitor with an IC₅₀ of 4.5 μM for murine tyrosinase and suppresses melanin biosynthesis. Gnetol has antioxidant, antiproliferative, anticancer and hepatoprotective activity. Gnetol also possesses concentration-dependent α-Amylase, α-glucosidase, and adipogenesis activities .

HY-W009732

Sinapinic acid 3 Publications Verification Sinapic acid	Monophenols other families Classification of Application Fields Simple Phenylpropanols Source classification Phenols Metabolic Disease Phenylpropanoids Plants Disease Research Fields	HDAC Angiotensin-converting Enzyme (ACE) Reactive Oxygen Species Apoptosis
Sinapinic acid (Sinapic acid) is a phenolic compound isolated from Hydnophytum formicarum Jack. Rhizome, acts as an inhibitor of *HDAC, with an IC₅₀* of 2.27 mM , and also inhibits ACE-I activity . Sinapinic acid posssess potent anti-tumor activity, induces apoptosis of tumor cells . Sinapinic acid shows antioxidant and antidiabetic activities . Sinapinic acid reduces total cholesterol, triglyceride, and HOMA-IR index, and also normalizes some serum parameters of antioxidative abilities and oxidative damage in ovariectomized rats .

HY-B0809

Theophylline 5+ Cited Publications 1,3-Dimethylxanthine; Theo-24	Structural Classification Classification of Application Fields Source classification Plants Camellia sinensis (L.) O. Ktze. Endogenous metabolite Alkaloids Microorganisms Immune System Disorder Disease markers Disease Research Fields Cancer Theaceae	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite
Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-B0809B

Theophylline sodium acetate 1,3-Dimethylxanthine sodium acetate; Theo-24 sodium acetate	Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor
Theophylline (1,3-Dimethylxanthine) sodium acetate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) sodium acetate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) sodium acetate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) sodium acetate induces apoptosis. Theophylline (1,3-Dimethylxanthine) sodium acetate can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-B0809R

Theophylline (Standard) 1,3-Dimethylxanthine(Standard); Theo-24 (Standard)	Structural Classification Alkaloids Immune System Disorder Classification of Application Fields Source classification Disease markers Plants Camellia sinensis (L.) O. Ktze. Endogenous metabolite Disease Research Fields Cancer Theaceae	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite
Theophylline (Standard) is the analytical standard of Theophylline. This product is intended for research and analytical applications. Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-N7676

Marein	Cardiovascular Disease Flavonoids Chalcones other families Classification of Application Fields Neurological Disease Source classification Phenols Polyphenols Plants Disease Research Fields	AMPK HDAC
Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a *HDAC* inhibitor with an IC₅₀ of 100 µM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects .

HY-13755

Sulforaphane 30+ Cited Publications	Structural Classification Natural Products other families Classification of Application Fields Source classification Plants Inflammation/Immunology Disease Research Fields	HDAC Keap1-Nrf2 Apoptosis Bcl-2 Family Caspase Reactive Oxygen Species
Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of *HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1* expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties .

Cat. No.	Product Name	Chemical Structure

HY-12163S

Entinostat-d4
Entinostat-d₄ is the deuterium labeled Entinostat[1]. Entinostat is an oral and selective class I HDAC inhibitor, with IC50s of 243 nM, 453 nM, and 248 nM for HDAC1, HDAC2, and HDAC3, respectively[2].

HY-10585AS1

Valproic acid-d14 sodium

Valproic acid-d₁₄ (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-109015S

Tucidinostat-d4
Tucidinostat-d₄ is the deuterium labeled Tucidinostat. Tucidinostat is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, respectively[1].

HY-10585AS

Valproic acid-d7 sodium

Valproic acid-d₇ (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S3

Valproic acid-d4 sodium

Valproic acid-d₄ (sodium) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-10585S4

Valproic acid-d4-1

Valproic acid-d₄-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S2

Valproic acid-d15

Valproic acid-d₁₅ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S

Valproic acid-d4

Valproic acid-d₄ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S1

Valproic acid-d6

Valproic acid-d₆ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-B0809S

Theophylline-d6
Theophylline-d₆ is the deuterium labeled Theophylline. Theophylline is a nonselective phosphodiesterase (PDE) inhibitor, adenosine receptor blocker, and histone deacetylase (HDAC) activator.

HY-15654S

Phenylbutyrate-d11 sodium
Phenylbutyrate-d₁₁ (sodium) is deuterium labeled Sodium 4-phenylbutyrate. Sodium 4-phenylbutyrate (4-PBA sodium) is an inhibitor of HDAC and endoplasmic reticulum (ER) stress, used in cancer and infection research[1].

HY-A0281S

4-Phenylbutyric acid-d11
4-Phenylbutyric acid-d₁₁ is the deuterium labeled 4-Phenylbutyric acid. 4-Phenylbutyric acid (4-PBA) is an inhibitor of HDAC and endoplasmic reticulum (ER) stress, used in cancer and infection research.

HY-A0281S3

4-Phenylbutyric acid-d2
4-Phenylbutyric acid-d₂ is the deuterium labeled 4-Phenylbutyric acid[1]. 4-Phenylbutyric acid (4-PBA) is an inhibitor of HDAC and endoplasmic reticulum (ER) stress, used in cancer and infection research.

HY-A0281S2

4-Phenylbutyric acid-d5
4-Phenylbutyric acid-d₅ is the deuterium labeled 4-Phenylbutyric acid[1]. 4-Phenylbutyric acid (4-PBA) is an inhibitor of HDAC and endoplasmic reticulum (ER) stress, used in cancer and infection research[2][3][4].

HY-10528S

Tasquinimod-d3
Tasquinimod-d3 (ABR-215050-d3) is the deuterium labeled Tasquinimod (HY-10528). Tasquinimod is an oral antiangiogenic agent, which plays an important role in castration-resistant prostate cancer. Tasquinimod binds to the regulatory Zn ²⁺ binding domain of *HDAC4* with K_d of 10-30 nM. Tasquinimod also is a S100A9 inhibitor .

HY-10224S

Panobinostat-d4

Panobinostat-d₄ is the deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

HY-10224S1

Panobinostat-d4 hydrochloride

Panobinostat-d₄ (hydrochloride) is deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

Cat. No.	Product Name		Classification

HY-142706

MAO A/HDAC-IN-1		Alkynes
MAO A/HDAC-IN-1 is a dual?inhibitor?of monoamine oxidase A (MAO A) and *HDAC. MAO A/HDAC-IN-1 can be used for glioma research . MAO A/HDAC*-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-163143

HDAC8-IN-6

Alkynes

HDAC8-IN-6 (compound 3) is a potent HDAC8 inhibitor with an IC₅₀ of 5.1 μM. HDAC8-IN-6 shows cytotoxicity .

HY-151872

HDAC-IN-48		Alkynes
HDAC-IN-48 is a potent *HDAC* inhibitor. HDAC-IN-48 is a hybrid molecule with great cytotoxic profile (GI₅₀~20 nM). HDAC-IN-48 consists of harmacophores of SAHA and CETZOLE molecules. HDAC-IN-48 induces ferroptosis and inhibits *HDAC* proteins . HDAC-IN-48 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-145259

HDAC6-IN-3		Alkynes
HDAC6-IN-3 (Compound 14), an antiprostate cancer agent, is a potent, orally active *HDAC6* inhibitor with IC₅₀s ranging from 0.02-1.54 μM for HDAC1/2/3/6/8/10. HDAC6-IN-3 is also an effective MAO-A (IC₅₀=0.79 μM) and LSD1 inhibitor . HDAC6-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-126943

SAHA-BPyne		Alkynes
SAHA-BPyne is an activity-based protein profiling (ABPP) probe for detecting HDAC activity, which covalently labels the proximal proteins through a photoactivation. SAHA-BPyne inhibits HDAC activity in HeLa nuclear lysate with an IC₅₀ of less than 5 μM .

HY-118783

2-Hexyl-4-pentynoic acid (±)-2-Hexyl-4-pentynoic acid		Alkynes
2-Hexyl-4-pentynoic acid ((±)-2-Hexyl-4-pentynoic acid), valproic acid (VPA) derivative, exhibits potential roles of HDAC inhibition (IC₅₀=13 μM) and HSP70 induction. Potent neuroprotective effects. 2-Hexyl-4-pentynoic acid causes histone hyperacetylation and protect against glutamate-induced excitotoxicity in cultured neurons . 2-Hexyl-4-pentynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10223

CUDC-101 5+ Cited Publications		Alkynes
CUDC-101 is a potent inhibitor of *HDAC, EGFR, and HER2* with IC₅₀s of 4.4, 2.4, and 15.7 nM, respectively. CUDC-101 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks